Clinical TrailsPfizer’s HYMPAVZI Secures FDA Priority Review for Kids Pfizer’s HYMPAVZI Secures FDA Priority Review for Kids Read Post »
Clinical TrailsFDA Grants Orphan Drug Designation to Zenocutuzumab for NRG1-Fusion Cholang... FDA Grants Orphan Drug Designation to Zenocutuzumab for NRG1-Fusion Cholang... Read Post »
Clinical TrailsBayer’s Asundexian Cuts Stroke Risk 26% in Phase III Bayer’s Asundexian Cuts Stroke Risk 26% in Phase III Read Post »
Clinical TrailsUCB’s BIMZELX Achieves 3-Year HS Control: BE HEARD Trial Data Reveale... UCB’s BIMZELX Achieves 3-Year HS Control: BE HEARD Trial Data Reveale... Read Post »
Clinical TrailsFDA Fast Tracks Cumberland’s Ifetroban for DMD Heart Disease FDA Fast Tracks Cumberland’s Ifetroban for DMD Heart Disease Read Post »
Clinical TrailsAstellas Fezolinetant Cuts Menopausal VMS in Japan Phase 3 Astellas Fezolinetant Cuts Menopausal VMS in Japan Phase 3 Read Post »
Clinical TrailsImmunityBio Launches Phase 2 ResQ215B Trial for Indolent B-Cell Lymphoma ImmunityBio Launches Phase 2 ResQ215B Trial for Indolent B-Cell Lymphoma Read Post »
Clinical TrailsNovo Nordisk’s CagriSema Outperforms Semaglutide in REIMAGINE 2 Trial Novo Nordisk’s CagriSema Outperforms Semaglutide in REIMAGINE 2 Trial Read Post »
Clinical TrailsPfizer Bets Big on Monthly GLP-1 After Metsera Deal, VESPER-3 Hits Key Endp... Pfizer Bets Big on Monthly GLP-1 After Metsera Deal, VESPER-3 Hits Key Endp... Read Post »
Clinical TrailsJohnson & Johnson Unveils Real-World Data: ERLEADA Cuts Death Risk by 5... Johnson & Johnson Unveils Real-World Data: ERLEADA Cuts Death Risk by 5... Read Post »
Clinical TrailsPositive Topline Results: Venglustat Succeeds in Sanofi’s LEAP2MONO GD3 S... Positive Topline Results: Venglustat Succeeds in Sanofi’s LEAP2MONO GD3 S... Read Post »
Clinical TrailsLundbeck INFUSE Study: Vyepti Shines for Hard-to-Treat Migraine Lundbeck INFUSE Study: Vyepti Shines for Hard-to-Treat Migraine Read Post »
Clinical TrailsUltragenyx Resubmits BLA for UX111 Gene Therapy in Sanfilippo Syndrome Type... Ultragenyx Resubmits BLA for UX111 Gene Therapy in Sanfilippo Syndrome Type... Read Post »
Clinical TrailsTanabe Pharma’s ZYNLONTA® Hits Key Endpoint in Japanese r/r DLBCL Tr... Tanabe Pharma’s ZYNLONTA® Hits Key Endpoint in Japanese r/r DLBCL Tr... Read Post »
Clinical TrailsFDA Grants Class II Review for Unicycive’s Resubmission of OLC in Hyperph... FDA Grants Class II Review for Unicycive’s Resubmission of OLC in Hyperph... Read Post »
Clinical TrailsChugai Files Tecentriq for MRD-Positive Bladder Cancer in Japan Chugai Files Tecentriq for MRD-Positive Bladder Cancer in Japan Read Post »
Clinical TrailsBiogen’s Litifilimab Wins FDA Breakthrough Therapy Designation for Cutane... Biogen’s Litifilimab Wins FDA Breakthrough Therapy Designation for Cutane... Read Post »
Clinical TrailsFDA Grants Priority Review to Otsuka’s Centanafadine NDA for ADHD Across ... FDA Grants Priority Review to Otsuka’s Centanafadine NDA for ADHD Across ... Read Post »
Clinical TrailsELEVIDYS Delivers 3-Year Sustained Motor Benefits in Ambulatory Duchenne Pa... ELEVIDYS Delivers 3-Year Sustained Motor Benefits in Ambulatory Duchenne Pa... Read Post »
Clinical TrailsNeurocrine Biosciences Launches Phase 2 Trial of NBI-1065890 for Tardive Dy... Neurocrine Biosciences Launches Phase 2 Trial of NBI-1065890 for Tardive Dy... Read Post »
Clinical TrailsRoche’s CT-388 Shows Up to 22.5% Placebo-Adjusted Weight Loss in Phase II... Roche’s CT-388 Shows Up to 22.5% Placebo-Adjusted Weight Loss in Phase II... Read Post »
Clinical TrailsFDA Accepts Eisai-Biogen’s LEQEMBI IQLIK sBLA Under Priority Review FDA Accepts Eisai-Biogen’s LEQEMBI IQLIK sBLA Under Priority Review Read Post »
Clinical TrailsBausch Health’s RED-C Program Comes Up Short in Phase 3 Bausch Health’s RED-C Program Comes Up Short in Phase 3 Read Post »
Clinical TrailsAbbott Shares Five-Year Data Showing Neuromodulation Therapy Cuts Pain-Rela... Abbott Shares Five-Year Data Showing Neuromodulation Therapy Cuts Pain-Rela... Read Post »
Clinical TrailsSanofi’s Amlitelimab Strengthens Phase 3 Evidence in Atopic Dermatitis wi... Sanofi’s Amlitelimab Strengthens Phase 3 Evidence in Atopic Dermatitis wi... Read Post »
Clinical TrailsCorcept Reports Overall Survival Benefit with Relacorilant in Platinum-Resi... Corcept Reports Overall Survival Benefit with Relacorilant in Platinum-Resi... Read Post »
Clinical TrailsBayer and BlueRock’s OpCT-001 Receives FDA Orphan Drug Designation for Re... Bayer and BlueRock’s OpCT-001 Receives FDA Orphan Drug Designation for Re... Read Post »
Clinical TrailsImmunityBio Advances ANKTIVA Toward FDA Resubmission in Papillary NMIBC ImmunityBio Advances ANKTIVA Toward FDA Resubmission in Papillary NMIBC Read Post »
Clinical TrailsFDA Grants Fast Track Designation to BioNTech’s BNT113 for HPV16-Positive... FDA Grants Fast Track Designation to BioNTech’s BNT113 for HPV16-Positive... Read Post »
Clinical TrailsFDA Grants Breakthrough Therapy Designation to Lilly’s Sofetabart Mipitec... FDA Grants Breakthrough Therapy Designation to Lilly’s Sofetabart Mipitec... Read Post »
Clinical TrailsModerna–Merck mRNA Cancer Vaccine Combo Shows Durable Five-Year Recurrenc... Moderna–Merck mRNA Cancer Vaccine Combo Shows Durable Five-Year Recurrenc... Read Post »
Clinical TrailsSimcere and Lynk Report Positive Phase III Data for Zemprocitinib in Modera... Simcere and Lynk Report Positive Phase III Data for Zemprocitinib in Modera... Read Post »
Clinical TrailsAxsome Therapeutics Doses First Patient in Phase 3 FORWARD Trial of AXS-14 ... Axsome Therapeutics Doses First Patient in Phase 3 FORWARD Trial of AXS-14 ... Read Post »
Clinical TrailsJohnson & Johnson Presents New Evidence That CAPLYTA With Antidepressan... Johnson & Johnson Presents New Evidence That CAPLYTA With Antidepressan... Read Post »
Clinical TrailsAbbVie and Genmab Report Phase 3 Results for Epcoritamab in Relapsed DLBCL AbbVie and Genmab Report Phase 3 Results for Epcoritamab in Relapsed DLBCL Read Post »
Clinical TrailsTeva’s AJOVY Demonstrates Strong Efficacy in Reducing Pediatric Migraine ... Teva’s AJOVY Demonstrates Strong Efficacy in Reducing Pediatric Migraine ... Read Post »
Clinical TrailsTanabe Pharma Reports Positive Phase 3 INSPIRE Results for MT-7117 in EPP a... Tanabe Pharma Reports Positive Phase 3 INSPIRE Results for MT-7117 in EPP a... Read Post »
Clinical TrailsPhase 3 MajesTEC-9 Trial Shows TECVAYLI® Monotherapy Improves Survival in ... Phase 3 MajesTEC-9 Trial Shows TECVAYLI® Monotherapy Improves Survival in ... Read Post »
Clinical TrailsBristol Myers Squibb Reports Positive Phase 3 SCOUT-HCM Results for Camzyos... Bristol Myers Squibb Reports Positive Phase 3 SCOUT-HCM Results for Camzyos... Read Post »
Clinical TrailsJohnson & Johnson’s RYBREVANT® Shows Promising Long-Term Results in ... Johnson & Johnson’s RYBREVANT® Shows Promising Long-Term Results in ... Read Post »
Clinical TrailsBepirovirsen Shows Phase III Success in Chronic Hepatitis B, GSK Confirms Bepirovirsen Shows Phase III Success in Chronic Hepatitis B, GSK Confirms Read Post »
Clinical TrailsLilly’s Taltz Plus Zepbound Delivers Superior Outcomes in Phase 3b Psoria... Lilly’s Taltz Plus Zepbound Delivers Superior Outcomes in Phase 3b Psoria... Read Post »
Clinical TrailsJohnson & Johnson Reports Positive Phase 2b JASMINE Trial Results for N... Johnson & Johnson Reports Positive Phase 2b JASMINE Trial Results for N... Read Post »
Clinical TrailsFull Phase 3 TULIP-SC Results Support Self-Administered Saphnelo for Lupus Full Phase 3 TULIP-SC Results Support Self-Administered Saphnelo for Lupus Read Post »
Clinical TrailsDenali’s Tividenofusp Alfa (DNL310) Phase 1/2 Data in Hunter Syndrome wit... Denali’s Tividenofusp Alfa (DNL310) Phase 1/2 Data in Hunter Syndrome wit... Read Post »
Clinical TrailsGalapagos GLPG3667 Meets Primary Endpoint in Dermatomyositis Phase 3-Enabli... Galapagos GLPG3667 Meets Primary Endpoint in Dermatomyositis Phase 3-Enabli... Read Post »
Clinical TrailsTirzepatide Matches Dulaglutide on Major Cardiovascular Outcomes in SURPASS... Tirzepatide Matches Dulaglutide on Major Cardiovascular Outcomes in SURPASS... Read Post »
Clinical TrailsJohnson and Johnson’s JNJ-5939 Falls Short in DUPLEX-AD Phase 2b Trial fo... Johnson and Johnson’s JNJ-5939 Falls Short in DUPLEX-AD Phase 2b Trial fo... Read Post »
Clinical TrailsBiogen Reports Final VALOR Results Showing Earlier QALSODY Treatment May Sl... Biogen Reports Final VALOR Results Showing Earlier QALSODY Treatment May Sl... Read Post »
Clinical TrailsNeurocrine’s Phase 3 KINECT-DCP Trial of Valbenazine Fails to Meet En... Neurocrine’s Phase 3 KINECT-DCP Trial of Valbenazine Fails to Meet En... Read Post »
